Many UK founders discover this the hard way: they incorporate an Indian company, only to find they still can't manufacture, import, or sell a single tablet. That's because registering a pharmaceutical company in India actually involves two separate tracks that happen to overlap.
- Creating an Indian legal entity through the Ministry of Corporate Affairs (MCA)
- Securing permission to carry out the specific regulated pharmaceutical activity you have in mind
The right route depends entirely on what you're planning: manufacturing formulations, importing finished medicines, distributing wholesale, marketing products, running clinical research, outsourcing production, or simply establishing a commercial presence.
This guide walks through entity selection, foreign investment rules, MCA incorporation, the pharmaceutical licences layered on top of company registration, documentation requirements, and alternatives to building your own manufacturing plant.
Key Takeaways
- MCA incorporation registers a legal entity; it does not authorise manufacturing, importing, wholesale distribution, or sale of medicines.
- Define your product and operating model before choosing between a private limited company, LLP, subsidiary, or joint venture.
- Confirm current FDI, FEMA, CDSCO, GST, and state drug-licensing requirements directly with Indian authorities before filing anything.
- Contract manufacturing, an Indian distributor, or an import-led model can work when a full manufacturing operation is premature.
How to Register a Pharmaceutical Company in India from the UK
Step 1: Define the Proposed Pharmaceutical Activity
Before touching an MCA form, decide exactly what your business will do in India. This single decision shapes every licence, regulator, and premises requirement that follows.
Ask whether you'll:
- Manufacture formulations or active pharmaceutical ingredients (APIs)
- Import finished medicines or bulk drugs
- Distribute products wholesale
- Market or brand products under your own label
- Conduct clinical research
- Operate as a contract or loan manufacturer
Then narrow the product category: finished formulations, APIs, biologics, medical devices, cosmetics, nutraceuticals, or controlled substances. Each follows a different pathway.
A nutraceutical falls under FSSAI rules, not CDSCO's drug framework, while a medical device sits under the separate Medical Devices Rules, 2017. Get this wrong, and you'll end up with a company registered for the wrong purpose, needing costly amendments later.
Step 2: Select the Indian Business Structure
Once the activity is clear, match it to a structure:
- Private limited company
- Limited Liability Partnership (LLP)
- Wholly owned subsidiary
- Joint venture
- Branch office
- Liaison office
Most UK pharmaceutical investors lean towards a private limited company. It's a separate legal entity with limited liability, can hold licences in its own name, and supports equity fundraising later.
An LLP can work too, but foreign investment into an LLP is only permitted where the sector allows 100% FDI under the automatic route with no performance conditions attached.
Branch and liaison offices are more restrictive. A branch office can import or export, conduct research, or act as the parent's buying and selling agent, but it generally can't manufacture directly, though subcontracting to an Indian manufacturer is possible.
A liaison office is purely a communication channel: no manufacturing, sales, or income-generating activity at all.
The final choice depends on your activity, funding plans, and liability appetite, so get tailored legal and tax advice before committing.
Step 3: Check Foreign Investment and India–UK Ownership Requirements
Foreign investment into Indian pharmaceuticals follows different rules depending on the project type, according to DPIIT's Consolidated FDI Policy:
- Greenfield projects (new manufacturing facilities): 100% FDI allowed under the automatic route
- Brownfield projects (investing in existing companies): 100% FDI permitted overall, but only up to 74% is automatic, with anything beyond needing Government approval
Brownfield deals also carry conditions: no non-compete clauses in most cases, maintaining production of essential medicines, and technology-transfer disclosures.
Beyond the sector cap, you'll handle India's foreign-exchange side too: routing funds through an authorised-dealer bank, getting a proper valuation, and filing reports such as FC-GPR (within 30 days of share issue) and the annual FLA return.
Don't rely on a blanket "100% ownership allowed" assumption. Confirm the current position with DPIIT, the RBI, and FEMA rules for your exact product category before wiring any money.
Step 4: Prepare and File the MCA Incorporation Application
Incorporating the Indian entity runs through the MCA's SPICe+ portal, covering:
- Company name reservation (Part A)
- Incorporation details, directors, subscribers, and share capital (Part B)
- Memorandum and Articles of Association (e-MOA/e-AOA)
- Registered office address in India
- PAN and TAN application, bundled into the same filing
For UK shareholders and directors, expect extra documentation: notarised and apostilled copies of passports and proof of address, plus, for a UK corporate shareholder, its certificate of incorporation and a board resolution authorising the investment. The UK Legalisation Office handles the apostille step for documents signed or certified in the UK.
Your objects clause matters more than most founders realise. A vague description of "trading activities" won't reflect an actual pharmaceutical business and can trigger queries later. Describe the intended activity precisely. Always verify current SPICe+ form versions, fees, and attachment rules on the live MCA portal before filing.
Step 5: Establish the Operating and Regulatory Foundation
Once incorporated, the company needs operating infrastructure before any drug-related licence application makes sense:
- PAN, TAN, and a company bank account
- GST registration, where the activity requires it
- Accounting and bookkeeping systems from day one
Then identify your regulatory home. Manufacture, sale, and distribution of drugs is primarily overseen by State Drug Control authorities, while CDSCO handles central functions such as new-drug approval and import control. Which one applies, and which state, depends on where your premises sit and what you're doing.
If manufacturing is on the table, premises need to satisfy Good Manufacturing Practice expectations under Schedule M, along with qualified technical staff, validated equipment, and a Site Master File. Budget real time for premises fit-out and inspection readiness, not just paperwork.
Step 6: Apply for Activity-Specific Pharmaceutical Permissions
This is where company registration and pharmaceutical licensing genuinely diverge:
| Activity | Typical route |
|---|---|
| Manufacturing (own site) | State manufacturing licence (Forms 25/28 series) |
| Contract/loan manufacturing | Loan licence under Rule 75-A (Form 27-A) |
| Wholesale distribution | Forms 20B/21B via state licensing authority |
| Import of finished drugs/APIs | CDSCO registration (Form 40) plus import licence (Form 10) |
| Clinical research | CDSCO approval under the New Drugs and Clinical Trials Rules, 2019 |
For imports specifically, CDSCO's import guidance requires both the drug and the manufacturing site to be registered before the product can enter India, with the registration certificate issued in Form 41.
Treat these as separate applications, not one bundled "pharma licence." A company can be fully incorporated and still be months away from legally selling anything.
Step 7: Launch Only After Commercial and Compliance Checks
Before the first commercial sale, lock down who's responsible for what:
- Manufacturer, importer of record, distributor, and marketing-authorisation holder
- Quality-responsible party and pharmacovigilance contact
- Product owner in contract-manufacturing arrangements
Put this in writing through supply and quality agreements. Verbal understandings don't hold up during an inspection or a recall.
You'll also need working systems for:
- Batch traceability
- Adverse-event reporting
- Product recalls
- Temperature-controlled storage where relevant
- Product-liability insurance
Registration doesn't end the workload either: expect ongoing MCA annual filings, tax obligations, licence renewals, and periodic regulatory reporting for as long as the company operates.
When Should You Register a Pharmaceutical Company in India from the UK?
An Indian entity earns its keep when you need boots on the ground. Incorporation is usually the right move if you need:
- Local manufacturing under your own control
- Direct sales staff on Indian-law employment contracts
- A subsidiary that can hold drug licences in its own name
- Supply-chain control from raw materials through to the pharmacy shelf
Full incorporation isn't always the first move, though. Consider these alternatives:
- Distributor partnership – an existing Indian wholesaler handles sales and logistics under its own licences
- Contract manufacturer – your product gets made under a loan licence arrangement, without you owning a plant
- Licensing partner – an Indian company manufactures and markets under a technology or brand licence
- Import-led model – you register the product and site with CDSCO and route sales through a local agent
| Model | Investment | Control | Compliance burden | Speed |
|---|---|---|---|---|
| Wholly owned subsidiary | High | Highest | Highest | Slowest |
| Joint venture | Medium-high | Shared | High | Medium |
| Contract manufacturing | Low-medium | Medium | Medium | Faster |
| Distributor-led | Low | Lowest | Lowest | Fastest |
For UK businesses weighing these options, company formation, accounting, tax, and FEMA/FDI reporting are usually the practical starting point. VJM Global handles that corporate and compliance groundwork while your pharmaceutical regulatory advisors manage CDSCO and state drug-licensing specifics.
What You Need Before Registering
Equipment and system requirements
What you need depends on whether you'll own a plant or use a contract manufacturer:
- Owning a plant: GMP-validated equipment, warehousing, cold-chain or controlled storage where relevant, lab access, and a documented quality-management system
- Contract manufacturer or 3PL: vendor qualification, quality agreements, batch-release oversight, and inventory/traceability systems at your partner's site
Either way, you'll need IT systems that support batch records and complaint handling.
Inputs, materials, and conditions
Before filing anything, gather:
- Product catalogue and dosage forms
- Manufacturing route (own site vs. contract manufacture)
- Proposed Indian state for incorporation and operations
- Ownership chart and source of funds
- Business plan and supply-chain model
- UK shareholder identity and corporate documents
Product classification, composition, manufacturing site, and marketing claims can all shift which approval pathway applies. A "health supplement" claim, for instance, can move a product out of CDSCO's drug framework entirely and into FSSAI's.
Skill, safety, and compliance readiness
Regulated pharmaceutical operations need qualified people and complete documentation:
- Qualified technical personnel and, where applicable, a responsible pharmacist
- Dedicated quality and regulatory staff
- Documented Standard Operating Procedures and training records
Check the current rules that apply to your product:
- GMP and pharmacovigilance
- Clinical research and controlled substances
- Environmental permissions and hazardous-material handling
Pre-filing checklist:
- Apostilled UK identity and corporate documents
- Board resolutions and powers of attorney
- Beneficial-owner information
- Registered-office proof in India
- Financial projections and source-of-funds evidence
Key Regulatory and Operational Parameters That Affect Results
An incorporation certificate confirms your company exists. It says nothing about what that company is allowed to do. That comes down to product, ownership, premises, and classification.
Product and Activity Classification
Each product type sits under different laws and regulators:
- Finished medicines
- APIs
- Biologics
- Medical devices
- Cosmetics
- Nutraceuticals
A biologic may trigger the New Drugs and Clinical Trials Rules, 2019, while a device follows the separate Medical Devices Rules.
Get the classification wrong, and product registration, manufacturing approval, labelling, and advertising follow the wrong pathway—sometimes requiring a full restart.
Ownership, Investment, and Corporate Structure
These structural choices shape your approval route and reporting obligations:
- Foreign ownership limits
- Greenfield vs. brownfield status
- Joint-venture terms
- Beneficial ownership
- Board composition
A wholly owned greenfield subsidiary faces a different FDI pathway than a 74% brownfield acquisition. Confirm current FDI and FEMA/RBI requirements for your scenario—India's pharmaceutical FDI policy has shifted before.
Premises, Manufacturing Standards, and Technical Personnel
Inspection readiness depends on several operational controls:
- State-specific premises approvals
- GMP expectations under Schedule M
- Qualified technical personnel
- Equipment validation
- Batch-release documentation
If production is outsourced to an approved contract manufacturer, many of these requirements sit with your partner. You still need written quality agreements confirming who is accountable for what.
Import, Distribution, and Supply-Chain Responsibility
Document, in writing, who holds each supply-chain role:
- Importer of record
- Customs party
- Warehouse operator
- Wholesaler
- Product owner
- Quality contact
Temperature control, batch traceability, recall procedures, and pharmacovigilance also need clear ownership. Without that clarity, one product recall can become a finger-pointing exercise across three or four parties.
Tax, Customs, and Ongoing Compliance
Plan for these ongoing obligations from day one:
- GST
- Customs classification by HS code
- Transfer pricing on related-party transactions
- Withholding tax
- Annual MCA filings
- Statutory audit
- Licence renewals
The India-UK double taxation treaty generally taxes business profits only in the country of residence, unless there is a permanent establishment in the other country.
Get specific treaty advice on dividends, royalties, and technical service fees for your structure, rather than relying on general summaries.
Common Mistakes, Troubleshooting and Alternatives
Most registration and licensing delays come from a small set of avoidable errors.
Common Registration Mistakes
- Skipping product classification first — incorporating before you confirm drug, device, cosmetic, or nutraceutical status
- Treating MCA registration as a pharma licence — it does not cover manufacture, import, wholesale, or sale
- Using a generic objects clause — wording that ignores the actual pharmaceutical activity planned
- Filing UK documents unprepared — missing apostille, notarisation, or translation checks
- Funding before FDI/FEMA review — capital introduced without valuation and route checks
- Locking premises too early — site chosen before GMP and state-licensing constraints are clear
If an Application Stalls
Work through these checks in order:
- Document authentication (apostille, notarisation, translation)
- Name or objects-clause objections from the MCA
- Incomplete ownership or beneficial-owner information
- Missing premises or technical-personnel evidence
- Incorrect product classification
- Inspection findings from the drug-control authority
Alternatives to Full Incorporation
If full incorporation feels premature, consider:
- Contract manufacturing — lower upfront cost; define quality agreements and batch-release responsibility
- Indian distributor — fastest market access, least operational control
- Licensing arrangement — Indian partner handles manufacture and marketing
- Joint venture — shared investment and risk with a local partner
- Import-led company — keep UK manufacture; handle Indian registration and distribution locally
Each option trades control for speed and compliance load. Choose based on how much operational control you need in India, not on a single “best” structure.
Conclusion
A UK founder can build a pharmaceutical business in India. Incorporation is only the opening move in a longer process covering foreign investment rules, MCA filings, product classification, premises approval, and activity-specific drug licences.
The right route depends on what you will actually do:
- Manufacturing
- Importing or distributing
- Marketing
- Contract production
- Research
- Maintaining a commercial presence
Each path needs its own mix of entity structure, FDI treatment, and regulatory approval.
Before you commit funds or sign a lease, confirm current requirements with the MCA, DPIIT, RBI, CDSCO, your State Drug Control authority, and GST or tax advisors. Foreign ownership and drug licensing rules shift, so yesterday’s guidance is not a safe basis for today’s filing.
VJM Global supports UK businesses with India entity formation, FEMA/FDI advisory, and compliance sequencing across these steps.
Frequently Asked Questions
Can a UK citizen or UK company register a pharmaceutical company in India?
Yes. UK individuals and companies can establish or own an Indian entity, subject to Indian incorporation rules, foreign-investment conditions, identity documentation, and sector-specific pharmaceutical requirements.
What type of company should a UK investor establish in India?
Common options include a private limited company, LLP, subsidiary, or joint venture. The right choice depends on your ownership plans, activity, funding needs, and liability tolerance.
Does incorporation automatically allow the company to manufacture or sell medicines?
No. Incorporation creates the legal entity, but manufacturing, import, wholesale distribution, and sale of medicines each require separate drug-control and product approvals.
What licences are required to operate a pharmaceutical company in India?
Requirements vary by product and activity, and can include CDSCO registration, State Drug Control licences, manufacturing or wholesale permits, import registration, GMP compliance, and GST registration.
Can a UK company own 100% of an Indian pharmaceutical company?
It depends on whether the investment is greenfield or brownfield and which FDI route applies. Confirm the current position with DPIIT and RBI before assuming full ownership is automatic.
Can a UK investor use contract manufacturing instead of building a plant?
Yes. Contract manufacturing lowers upfront investment, but both parties must clearly define licences, quality agreements, batch-release responsibility, and pharmacovigilance obligations.
